Charles Rhyee
Cowen & Company
[email protected]
646-562-1376
We are positive on CVS Health in the near term for its strong pharmacy benefits management (PBM) business and Hepatitis C sales, as well as in the long-term for its positioning on health reform with its integrated PBM/retail business model. We believe management is steering the company in the right direction with a number of long-term growth drivers such as the Cardinal Health/CVS sourcing joint venture, the growing clinics business, Pharmacy Advisor and Coram. We still see favorable risk/reward and think it should be a core holding for any healthcare investor.
While investors are concerned with margins in 2016, and particularly whether reimbursement rate pressure is getting worse than expected, management does not see [them] as any worse than [its] own estimates. Given [its] track record, we are inclined to believe this and note margins should be coming down, primarily due to faster growth from low margin areas and some timing issues that should reverse in 2017.
Despite disappointing the high bar that has been set, it's important to remember CVS is still meeting its long-term target of 10-14% growth with its preliminary 2016 guidance. The growth strategy remains focused on growing covered lives in the PBM and retail share through their integrated operations to win as an enterprise, and the move to digital outreach also helps to engage and offset the ongoing margin pressure faced by the business.
Additionally, disciplined capital allocation [strategies] as a mix of dividends, buybacks and mergers & acquisitions remain positive drivers as well. CVS remains a strong operator and steward of capital, with $4 billion in share repurchases expected to be completed in 2016, and remains on track to hit its targeted dividend payout ratio of 35% by 2018.
While the adjusted debt/earnings before interest, taxes, depreciation and amortization (EBITDA) ratio has risen a bit over 3.2 times due to recent incremental deal-related debt, management is focused on getting back to its 2.7 times target, which its strong cash flow generation should enable. For 2015, management expects free cash flow of $5.9 billion to $6.2 billion, and we would expect modest growth on this strong base in 2016 as well.
We maintain our 2015 adjusted EPS at $5.18 but lower out 2016 adjusted EPS estimate to $5.78 from $5.98. We also lowered our price target to $109 from $113 based on our revised five-year discounted cash flow [analysis], which implies shares can trade at 18.9 times our 2016 adjusted EPS estimate of $5.78.
John W. Ransom
Raymond James
800-248-8863
We reiterate our outperform rating on CVS Health shares following in-line 3Q15 results … Rather than focus on the quarter, we believe it is more prudent to address what may have changed since we last addressed CVS' out-year growth on Sept. 23.
We now model $1.53 in 4Q15 EPS (+$0.02), reflecting $5.16 in 2015 estimated EPS (unchanged), which is consistent with management's $5.14-$5.18 outlook. Note that our prior model assumed a Dec. 31, 2015 Omnicare (OCR) deal close, making comparisons less comparable.
In 2016, we now model $10.8 billion in EBIT (-$0.4 billion) and $5.85 in EPS (-$0.15); this compares to management's $5.68-$5.88 preliminary 2016 outlook. Our 2016 EPS estimate contemplates 4% organic EBIT growth, unchanged assumptions for OCR and Target, and a smaller benefit from 2016 net new business.
CVS trades at 16.9 times our 2016 non-GAAP EPS estimate, slightly above its historical spread relative to the S&P 500. Our $120 price target is based on a 20.5 times multiple on 2016 EPS, reflecting continued confidence in longer-term double-digit EPS growth targets.
Ghansham Panjabi, Ph.D.
Robert W. Baird & Co.
[email protected]
214-373-2955
Consolidated revenue for RPM International (RPM) improved moderately during 1FQ16 (quarter ended Aug. 31, 2015) as sales declines in industrial (–4.5%) and in consumer (–8.0%) were offset by the addition and resegmentation activities in the new specialty segment (+130.7% year over year).
Substantial North American weather-related headwinds were unfavorable (particularly for consumer) during 1FQ16 and foreign exchange (FX), both translational and transactional, negatively affected sales/profits.